SCHEMBL15745367

SCHEMBL15745367

CCCNc1ccc2c(ccn2-c2cccc(OC(F)(F)F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.48
DGAT1 O75907 2/20 0.42
CHRNA7 P36544 1/20 0.37
GRM2 Q14416 1/20 0.37
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
KCNH2 Q12809 2/20 0.35
RXRA P19793 2/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2B Q13224 2/20 0.35
FLT1 P17948 1/20 0.35
KDR P35968 1/20 0.35
F2 P00734 1/20 0.35
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18661369 0.89 DGAT1 (0.42) PIM1DGAT1FLT1KDRF2
SCHEMBL15733007 0.84 DGAT1 (0.42) PIM1DGAT1KCNH2RXRAGRIN1
SCHEMBL16167708 0.81 DHODH (0.44) KCNH2F2F10PRSS1MEN1
SCHEMBL6233653 0.77 PIM1 (0.50) PIM1ICMT
SCHEMBL15733052 0.77 DGAT1 (0.47) PIM1DGAT1KCNH2RXRAGRIN1
SCHEMBL2364027 0.73 DHODH (0.42) KCNH2
SCHEMBL6844833 0.73 ROCK2 (0.51) PIM1DGAT1RXRAMEN1KMT2A
SCHEMBL16167711 0.73 STIM1 (0.36) DGAT1CHRNA7KCNH2KDR
SCHEMBL15745368 0.72 DGAT1 (0.39) DGAT1KCNH2
SCHEMBL16720018 0.71 DGAT1 (0.42) PIM1DGAT1KCNH2RXRAGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099979-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC 2018-04-12 US disclosed
US-9879031-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC (US) 2018-01-30 US disclosed
US-20170305928-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC 2017-10-26 US disclosed
US-9796729-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC (US) 2017-10-24 US disclosed
US-9738658-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC (US) 2017-08-22 US disclosed
US-20170081342-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC 2017-03-23 US disclosed
US-20150322082-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-11-12 US disclosed
US-20140148437-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099979-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT PIM1 1484/4885DGAT1 1/4885CHRNA7 4518/4885
US-20170081342-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, LCAT PIM1 3739/4885DGAT1 1/4885CHRNA7 4089/4885
US-20140148437-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, LCAT PIM1 3739/4885DGAT1 1/4885CHRNA7 4089/4885
US-20170305928-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT PIM1 1524/4885DGAT1 1/4885CHRNA7 4602/4885
US-20150322082-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, LCAT PIM1 3739/4885DGAT1 1/4885CHRNA7 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.